CROWN BIOSCIENCE

OmniScreen Large Scale Cancer Cell Line Screening Technology

Find the right fit between a cancer cell and your therapeutic molecule

Assess the efficacy and potency of your oncology drug candidates by running initial screens with our large-scale cancer cell line panels. Take control of your experiment with Omni**Screen**™ and get unrivaled flexibility to design the screening panels you need.

Real-time Readouts

Adapt your experiments and optimize final results based on incoming data

- Monitoring in real-time via secure online client accounts
- Enhanced cell panel growth data for improved screening quality
- Weekly updates on a drug candidate's effectiveness

Embedded Quality Controls

Ensure screening results between cancer cell types are consistent

- · Cell line quality
 - Annotated, well-characterized, SNP/STR verified, mycoplasma tested
- Differences between cell culture media
- Variations in incubation times and treatment responses
- Seeding densities across multiple time points
- Chemotherapeutic agents, and vehicle controls

Focused Screening Panels

Remove the guessing and group cell lines together based on certain characteristics

- OmniPanel™: a growing collection of more than 520 cancer cell lines
- Xeno**Select**™: over 210 cancer cell lines with corresponding xenograft models to rapidly move to *in vivo* studies
- RNAseqPanel: over 240 cell lines with in-house RNAseq data for target identification
- PrimePanel™: a growing collection of over 30 primary cancer cells derived from PDX models for improved clinical relevance
- Custom built panel: using cell lines selected through XenoBase®

Fixed Option Screening Schedules

Cut costs and increase efficiency

- Screening runs every 3 months
- Any subpanel of 50 or more cell lines can be scheduled
- Internal drug controls and cell line revival costs are covered by Crown Bioscience

500+ cell lines

Based on expertly curated panels or custom built from existing cell line databases

30+ molecules

Choose from a variety of different molecules including kinase inhibitors, antibodies, antibody-drug conjugates, epigenetic modulators, and small and large molecules across tissue types

30+ indications

Covering multiple cancer indications



Advanced Assay Setups

Customize your study with flexible template designs

- 3D cell panel screening options
- Multiple incubation times
- Extended incubation times up to 10 days
- Multiplexed readouts

Bioinformatics Support

Receive personalized support from our bioinformatics team for novel targets and biomarkers

- Dose-response curve graphs
- Combination index graphs
- Inhibition heat maps for concentration combinations
- 2D contour maps
- 3D response surface plots
- Guided analysis and reporting

Combination Assays and Screens

Evaluate and quantify drug combinations effects

- Combination assays and screens, including proprietary CrownSyn™ drug combination analysis service
- Visualize and characterize combination effects as synergistic, antagonistic, or additive
- Determine optimal doses for further safety and efficacy studies


Historical Data

Maintain clear relevance to *in vivo* models and real-life clinical settings

- Omni**Screen**™ draws upon historical data from over 100 studies
- Make informed predictions on cell line growth parameters and responses to specific drug candidates based on how specific cell lines previously responded to drug candidates

OmniScreen - Cell-Based Screening Service

Novel Target & Hypothesis



Get in touch



Sales

US: +1 858 622 2900 **UK:** +44 870 166 6234





